LadRx Corporation, Inc. to Present at the Virtual Life Science Investor Forum March 13th
LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates
LadRx Strategic Shifts in Licensing and Royalty Agreements
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
